Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071904
Chunk: 74

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 74
---
     |      |     — |     |            |   35 |   |
| Personnel                               |     |                              |   107 |     |      |     — |     |            |  107 |   |
| Other                                   |     |                              |     7 |     |      |     — |     |            |    7 |   |
| Total R&D Discovery Project             |     |                              |   149 |     |      |     — |     |            |  149 |   |
| Total Research and Development Expenses |     | $                            | 2,456 |     | $    | 3,108 |     | $          | (652 | ) |

Research and development expenses for the three months ended March 31, 2025 and 2024 were $2.5 million and $3.1 million, respectively. The decrease was primarily attributed to reduced Chemistry, Manufacturing and Control development work related to SP-102. Selling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended March 31, 2025 and 2024 were $28.1 million and $29.3 million, respectively. The decrease of approximately $1.2 million was primarily due to a $1.8 million decrease in advisory and financing expenses, a $1.1 million decrease in personnel expense, primarily driven by a decrease in bonus accrual, a $1.2 million decrease in marketing expenses, a $0.5 million decrease in travel expenses, a $0.2 million decrease in insurance costs and a $1.1 million decrease in other expenses in the three months ended March 31, 2025, partially offset by a $3.1 million increase in contracted services and a $1.6 million increase in legal fees. Intangible Amortization Expense Intangible amortization expense for each of the three months ended March 31, 2025 and 2024 was $1.0 million. Legal Settlements Legal settlements for the three months ended March 31, 2025 and 2024 were nil and $6.9 million, respectively. The decrease was attributed to payments received from litigation settlements that were entered into during the first quarter

<div align='center'>42</div>

of 2024. See Note 11 titled “ Commitments and Contingencies ” to our consolidated financial statements in our Annual Report on Form 10-K. (Gain) Loss on Derivative Liability (Gain) loss